G-protein-coupled receptors as targets for gene transfer vectors using natural small-molecule ligands

Gene therapy for cystic fibrosis (CF) has focused on correcting electrolyte transport in airway epithelia. However, success has been limited by the failure of vectors to attach and enter into airway epithelia, and may require redirecting vectors to targets on the apical membrane of airway cells that...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biotechnology 2000-06, Vol.18 (6), p.635-640
Hauptverfasser: Kreda, Silvia M., Pickles, Raymond J., Lazarowski, Eduardo R., Boucher, Richard C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Gene therapy for cystic fibrosis (CF) has focused on correcting electrolyte transport in airway epithelia. However, success has been limited by the failure of vectors to attach and enter into airway epithelia, and may require redirecting vectors to targets on the apical membrane of airway cells that mediate these functions. The G-protein-coupled P2Y 2 receptor (P2Y 2 -R) is abundantly expressed on the airway lumenal surface and internalizes into coated pits upon agonist activation. We tested whether a small-molecule-agonist (UTP) could direct vectors to P2Y 2 -R and mediate attachment, internalization, and gene transfer. Fluorescein-UTP studies demonstrated that P2Y 2 -R agonists internalized with their receptor, and biotinylated UTP (BUTP) mediated P2Y 2 -R-specific internalization of fluorescently labeled streptavidin (SAF) or SAF conjugated to biotinylated Cy3 adenoviral-vector (BCAV). BUTP conjugated to BCAV mediated P2Y 2 -R-specific gene transfer in (1) adenoviral-resistant A9 and polarized MDCK cells by means of heterologous P2Y 2 -R, and (2) well-differentiated human airway epithelial cells by means of endogenous P2Y 2 -R. Targeting vectors with small-molecule-ligands to apical membrane G-protein-coupled receptors may be a feasible approach for successful CF gene therapy.
ISSN:1087-0156
1546-1696
DOI:10.1038/76479